ALSO NOTED: Becker takes the CEO spot at VIOQuest; J&J makes big changes; and much more...

> We figure Warren Buffett (photo) liked the idea. First, Berkshire Hathaway boosted its stake in Johnson & Johnson. Now, J&J has announced a sweeping reorganization. Report

> Chutes & Ladders: At the beginning of the week, Michael Becker was CEO of Cytogen. Now he's the CEO of VioQuest. Daniel Greenleaf resigned from VioQuest to pursue "other opportunities." Release

> Apotex has acquired Topgen of Belgium from Zambon. No acquisition price was disclosed. Release

> The FDA has spoken--and GlaxoSmithKline is breathing a sigh of relief. The agency did stiffen warnings on the embattled diabetes med Avandia, but it shied away from linking the drug to heart attacks. Report

> While all eyes were on other potential mergers, Hungary's Richter Gedeon made two deals that will boost it to the top of Central and Eastern Europe's pharma industry. Report

> Prompted by a study suggesting the drug may increase the risk of death, FDA has embarked on a safety review of Maxipime, a Bristol-Myers Squibb antibiotic. Report 

And Finally... An Iowa State professor makes the case that violent video games teach aggression. Release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.